As of 2025-05-29, the EV/EBITDA ratio of Qualigen Therapeutics Inc (QLGN) is -0.39. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. QLGN's latest enterprise value is 3.81 mil USD. QLGN's TTM EBITDA according to its financial statements is -9.78 mil USD. Dividing these 2 quantities gives us the above QLGN EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | - | - |
| Forward P/E multiples | - | - |
| Fair Price | - | - |
| Upside | - | - |
| Date | EV/EBITDA |
| 2025-05-27 | -0.38 |
| 2025-05-23 | -0.39 |
| 2025-05-22 | -0.39 |
| 2025-05-21 | -0.39 |
| 2025-05-20 | -0.39 |
| 2025-05-19 | -0.39 |
| 2025-05-16 | -0.40 |
| 2025-05-15 | -0.41 |
| 2025-05-14 | -0.39 |
| 2025-05-13 | -0.39 |
| 2025-05-12 | -0.38 |
| 2025-05-09 | -0.38 |
| 2025-05-08 | -0.38 |
| 2025-05-07 | -0.38 |
| 2025-05-06 | -0.37 |
| 2025-05-05 | -0.39 |
| 2025-05-02 | -0.37 |
| 2025-05-01 | -0.37 |
| 2025-04-30 | -0.38 |
| 2025-04-29 | -0.37 |
| 2025-04-28 | -0.37 |
| 2025-04-25 | -0.37 |
| 2025-04-24 | -0.38 |
| 2025-04-23 | -0.40 |
| 2025-04-22 | -0.40 |
| 2025-04-21 | -0.37 |
| 2025-04-17 | -0.35 |
| 2025-04-16 | -0.36 |
| 2025-04-15 | -0.36 |
| 2025-04-14 | -0.34 |
| 2025-04-11 | -0.33 |
| 2025-04-10 | -0.34 |
| 2025-04-09 | -0.35 |
| 2025-04-08 | -0.33 |
| 2025-04-07 | -0.34 |
| 2025-04-04 | -0.34 |
| 2025-04-03 | -0.36 |
| 2025-04-02 | -0.37 |
| 2025-04-01 | -0.37 |
| 2025-03-31 | -0.38 |
| 2025-03-28 | -0.39 |
| 2025-03-27 | -0.39 |
| 2025-03-26 | -0.36 |
| 2025-03-25 | -0.36 |
| 2025-03-24 | -0.35 |
| 2025-03-21 | -0.35 |
| 2025-03-20 | -0.34 |
| 2025-03-19 | -0.34 |
| 2025-03-18 | -0.35 |
| 2025-03-17 | -0.34 |